Evaluation of body composition during low-dose estrogen oral contraceptives treatment
- PMID: 9098463
Evaluation of body composition during low-dose estrogen oral contraceptives treatment
Abstract
Objective: To determine in a prospective study if the use of two low-dose estrogen oral contraceptives is associated with changes in weight or body composition.
Design: 80 outpatients referring to the family planning service, aged 18-43 years were randomly assigned to a treatment with the EE/desogestrel or EE/gestodene association, 20 patients with IUD, aged 26-40 years, were selected as a control group. Anthropometric data and body composition were taken at enrollment and after 6 and 12 months.
Main outcome measures: Anthropometric measurements included body mass index (BMI), body composition estimated by mean of Bioelectrical Impendance Analysis (BIA).
Results: In the three groups weight, BMI, and total body water (TBW), and body cellular mass (BCM) remained unchanged during the study period.
Conclusions: The use of EE/desogestrel and EE/gestodene is not associated with significant variations of body weight and body composition during one year treatment.
PIP: The effect of two low-dose oral contraceptives (OCs) on weight and body composition was evaluated in 80 family planning clinic outpatients 18-43 years of age. These women were randomly assigned to receive OCs containing either 20 mcg ethinyl estradiol and 150 mcg desogestrel or 30 mcg ethinyl estradiol and 75 mcg gestodene. 20 IUD users served as controls. Anthropometric measurements and body composition (estimated by Bioelectrical Impedance Analysis) were assessed at baseline and after 6 and 12 months of OC use. In all three groups, body weight, body mass index, total body water, and body cellular mass remained unchanged during the 12-month study period. These findings confirm that the new low-dose OCs have no significant effects on body weight or composition.
Similar articles
-
Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.Int J Fertil Menopausal Stud. 1995;40 Suppl 2:98-104. Int J Fertil Menopausal Stud. 1995. PMID: 8574257 Clinical Trial.
-
Treatment of hirsutism related to micropolycystic ovary syndrome (MPCO) with two low-dose oestrogen oral contraceptives: a comparative randomized evaluation.Acta Eur Fertil. 1990 May-Jun;21(3):139-41. Acta Eur Fertil. 1990. PMID: 2149912 Clinical Trial.
-
Clinical experience of a combined oral contraceptive with very low dose ethinyl estradiol.Acta Obstet Gynecol Scand Suppl. 1997;164:63-5. Acta Obstet Gynecol Scand Suppl. 1997. PMID: 9225641 Clinical Trial.
-
[Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].Minerva Ginecol. 2007 Aug;59(4):415-25. Minerva Ginecol. 2007. PMID: 17923832 Review. Italian.
-
[Pharmacodynamics of synthetic estrogens. Review article].Ginecol Obstet Mex. 1990 Oct;58:277-83. Ginecol Obstet Mex. 1990. PMID: 2292429 Review. Spanish.
Cited by
-
Lean Women on Metformin and Oral Contraceptives for Polycystic Ovary Syndrome Demonstrate a Dehydrated Osteosarcopenic Phenotype: A Pilot Study.Nutrients. 2019 Sep 2;11(9):2055. doi: 10.3390/nu11092055. Nutrients. 2019. PMID: 31480705 Free PMC article.
-
Combination contraceptives: effects on weight.Cochrane Database Syst Rev. 2014 Jan 29;2014(1):CD003987. doi: 10.1002/14651858.CD003987.pub5. Cochrane Database Syst Rev. 2014. PMID: 24477630 Free PMC article. Review.
-
Effects of oral contraceptives on diurnal profiles of insulin, insulin-like growth factor binding protein-1, growth hormone and cortisol in endurance athletes with menstrual disturbance.Hum Reprod. 2010 Jan;25(1):85-93. doi: 10.1093/humrep/dep350. Epub 2009 Oct 19. Hum Reprod. 2010. PMID: 19840988 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials